{"id":"asp0456","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3301675","moleculeType":"Protein","molecularWeight":"1526.77"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CDK9 inhibition is a strategy to block the transcriptional elongation process, which is crucial for the proliferation of cancer cells. By inhibiting CDK9, ASP0456 aims to suppress the growth of cancer cells and induce apoptosis.","oneSentence":"ASP0456 is a small molecule inhibitor of the CDK9 enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:25.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT07431957","phase":"PHASE4","title":"\"Efficacy and Safety of Linaclotide in Chronic Constipation\"","status":"NOT_YET_RECRUITING","sponsor":"Md Mehedi Shahriar","startDate":"2026-02-20","conditions":"Chronic Idiopathic Constipation, Irritable Bowel Syndrome (IBS-C), Chronic Constipation","enrollment":90},{"nctId":"NCT06692673","phase":"PHASE1, PHASE2","title":"Linaclotide for Colonoscopy Bowel Prep","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-12-01","conditions":"Patients Scheduled for Colonoscopy","enrollment":10},{"nctId":"NCT05796388","phase":"NA","title":"A Study of Virtual Reality and Linaclotide for IBS-C","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-31","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":65},{"nctId":"NCT04166058","phase":"PHASE3","title":"Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-11-19","conditions":"Irritable Bowel Syndrome With Constipation, Functional Constipation","enrollment":381},{"nctId":"NCT05760313","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-04-27","conditions":"Functional Constipation","enrollment":19},{"nctId":"NCT05107219","phase":"PHASE1","title":"GCC Agonist Signal in the Small Intestine","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2022-11-30","conditions":"Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm","enrollment":43},{"nctId":"NCT03796884","phase":"PHASE2","title":"Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2019-10-30","conditions":"Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8","enrollment":230},{"nctId":"NCT05652205","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-12-29","conditions":"Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)","enrollment":123},{"nctId":"NCT06989268","phase":"PHASE4","title":"Effect to Linaclotide on Colonic Motility","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-02-10","conditions":"Chronic Constipation","enrollment":10},{"nctId":"NCT06748638","phase":"PHASE4","title":"Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy","status":"ENROLLING_BY_INVITATION","sponsor":"Haifeng Lan","startDate":"2024-09-01","conditions":"Lactulose, Bowel Preparation","enrollment":444},{"nctId":"NCT06091735","phase":"NA","title":"Clinical Study of Bowel Preparation Before Colonoscopy","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2023-08-01","conditions":"Bowel Preparation","enrollment":444},{"nctId":"NCT01950403","phase":"PHASE1","title":"Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-09","conditions":"Colorectal Cancer, Healthy, no Evidence of Disease","enrollment":24},{"nctId":"NCT04026113","phase":"PHASE3","title":"Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-10-01","conditions":"Functional Constipation, Irritable Bowel Syndrome With Constipation","enrollment":438},{"nctId":"NCT02316899","phase":"PHASE3","title":"Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-21","conditions":"Irritable Bowel Syndrome With Constipation (IBS-C)","enrollment":500},{"nctId":"NCT02425722","phase":"PHASE2","title":"A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-04-13","conditions":"Chronic Constipation","enrollment":383},{"nctId":"NCT01714843","phase":"PHASE2","title":"A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-08-10","conditions":"Constipation-predominant Irritable Bowel Syndrome (IBS-C)","enrollment":559},{"nctId":"NCT03471728","phase":"","title":"Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-10-02","conditions":"Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases), Irritable Bowel Syndrome With Constipation (IBS-C)","enrollment":2475},{"nctId":"NCT02809105","phase":"PHASE3","title":"A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-06-24","conditions":"Chronic Constipation","enrollment":186},{"nctId":"NCT05291325","phase":"NA","title":"Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2022-05-25","conditions":"Bowel Preparation for Colonoscopy","enrollment":1607},{"nctId":"NCT05379491","phase":"NA","title":"Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation","status":"COMPLETED","sponsor":"Zhiguo Liu","startDate":"2022-08-01","conditions":"Colonoscopy","enrollment":720},{"nctId":"NCT04462900","phase":"","title":"Evaluate the Safety of Linaclotide in IBS-C Patients in China","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-18","conditions":"Irritable Bowel Syndrome-IBS","enrollment":3028},{"nctId":"NCT03119584","phase":"PHASE4","title":"Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation","status":"UNKNOWN","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2015-09-01","conditions":"Chronic Constipation, Diabete Mellitus","enrollment":23},{"nctId":"NCT02970591","phase":"NA","title":"A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2017-01","conditions":"Irritable Bowel Syndrome","enrollment":300},{"nctId":"NCT03336034","phase":"","title":"Assessment of Responsiveness to Treatment by Experience Sampling Method","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2018-01-01","conditions":"Constipation-predominant Irritable Bowel Syndrome","enrollment":16},{"nctId":"NCT04110145","phase":"PHASE2","title":"Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-10-14","conditions":"Functional Constipation","enrollment":35},{"nctId":"NCT05134584","phase":"PHASE4","title":"Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-01-01","conditions":"Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome","enrollment":78},{"nctId":"NCT02837783","phase":"PHASE4","title":"A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"TERMINATED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2016-12-21","conditions":"Irritable Bowel Syndrome Characterized by Constipation","enrollment":20},{"nctId":"NCT05137145","phase":"NA","title":"Effect and Safety of Polyethylene Glycol Combined With Linaclotide on Colon Cleansing for Patients With Chronic Constipation","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2021-09-01","conditions":"Bowel Preparation","enrollment":300},{"nctId":"NCT04532879","phase":"NA","title":"HygiRelief Procedure and HygiSample Evaluation for Functional Constipation","status":"WITHDRAWN","sponsor":"HyGIeaCare, Inc.","startDate":"2021-09","conditions":"Rome IV Functional Constipation","enrollment":""},{"nctId":"NCT03342287","phase":"","title":"Cognitive and Psychiatric Effects of Linaclotide on Patients With Constipation","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2016-03","conditions":"Constipation, Irritable Bowel Syndrome","enrollment":""},{"nctId":"NCT04804267","phase":"PHASE3","title":"Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-03-05","conditions":"Chronic Idiopathic Constipation","enrollment":750},{"nctId":"NCT02559817","phase":"PHASE2","title":"A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2015-11-01","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":101},{"nctId":"NCT02220348","phase":"PHASE1","title":"A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2014-07-31","conditions":"Breast Feeding, Constipation, Irritable Bowel Syndrome","enrollment":7},{"nctId":"NCT03573908","phase":"PHASE3","title":"A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2018-06-20","conditions":"Irritable Bowel Syndrome Characterized by Constipation","enrollment":614},{"nctId":"NCT02559206","phase":"PHASE2","title":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2015-10-22","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":759},{"nctId":"NCT02590432","phase":"PHASE4","title":"An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-11-01","conditions":"Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation","enrollment":828},{"nctId":"NCT02239510","phase":"NA","title":"Efficacy of Linaclotide to Senna for CIC","status":"TERMINATED","sponsor":"TriHealth Inc.","startDate":"2014-09","conditions":"Chronic Idiopathic Constipation","enrollment":9},{"nctId":"NCT02559570","phase":"PHASE2","title":"A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-11-03","conditions":"Functional Constipation in Children Ages 6-17 Years","enrollment":173},{"nctId":"NCT02270983","phase":"PHASE2","title":"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2014-10-31","conditions":"Opioid-Induced Constipation","enrollment":254},{"nctId":"NCT00765999","phase":"PHASE3","title":"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-10-31","conditions":"Chronic Constipation, Irritable Bowel Syndrome With Constipation","enrollment":1559},{"nctId":"NCT02078323","phase":"NA","title":"Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients","status":"COMPLETED","sponsor":"Augusta University","startDate":"2014-02","conditions":"Irritable Bowel Syndrome With Constipation (IBS-C)","enrollment":39},{"nctId":"NCT00730171","phase":"PHASE3","title":"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2008-09","conditions":"Irritable Bowel Syndrome With Constipation, Chronic Constipation","enrollment":1743},{"nctId":"NCT02291679","phase":"PHASE3","title":"Trial of Linaclotide in Patients With Chronic Idiopathic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2014-10","conditions":"Chronic Idiopathic Constipation","enrollment":1223},{"nctId":"NCT02360384","phase":"NA","title":"Caecal pH as a Biomarker for Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"Wingate Institute of Neurogastroenterology","startDate":"2015-11","conditions":"Irritable Bowel Syndrome","enrollment":48},{"nctId":"NCT01880424","phase":"PHASE3","title":"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-07","conditions":"Irritable Bowel Syndrome With Constipation (IBS-C)","enrollment":1722},{"nctId":"NCT02465385","phase":"PHASE4","title":"Single-dose Linaclotide for Capsule Endoscopy Preparation","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2015-02","conditions":"Crohn's, Ulcerative Colitis, Gastrointestinal Bleeding","enrollment":30},{"nctId":"NCT02781493","phase":"PHASE4","title":"Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2016-06","conditions":"Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopyp","enrollment":600},{"nctId":"NCT01642914","phase":"PHASE3","title":"Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-08","conditions":"Chronic Constipation, Constipation","enrollment":487},{"nctId":"NCT00938717","phase":"PHASE3","title":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2009-07","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":805},{"nctId":"NCT00402337","phase":"PHASE2","title":"Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2006-11","conditions":"Chronic Constipation","enrollment":310},{"nctId":"NCT00460811","phase":"PHASE2","title":"Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2007-04","conditions":"Irritable Bowel Syndrome With Constipation","enrollment":420},{"nctId":"NCT00948818","phase":"PHASE3","title":"Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-07","conditions":"Irritable Bowel Syndrome Characterized by Constipation","enrollment":803},{"nctId":"NCT00730015","phase":"PHASE3","title":"Trial of Linaclotide in Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2008-08","conditions":"Chronic Constipation","enrollment":643},{"nctId":"NCT00765882","phase":"PHASE3","title":"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-09","conditions":"Chronic Constipation","enrollment":633},{"nctId":"NCT01427387","phase":"PHASE1","title":"A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-06","conditions":"Healthy, Pharmacokinetics of ASP0456","enrollment":44},{"nctId":"NCT01279915","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10","conditions":"Healthy, Pharmacokinetics of ASP0456","enrollment":32},{"nctId":"NCT00306748","phase":"PHASE2","title":"Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Constipation","enrollment":40},{"nctId":"NCT00258193","phase":"PHASE2","title":"Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2006-01","conditions":"Irritable Bowel Syndrome","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["linaclotide","Linaclotide"],"phase":"phase_2","status":"active","brandName":"ASP0456","genericName":"ASP0456","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP0456 is a small molecule inhibitor of the CDK9 enzyme. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}